Europe ADHD Therapeutics Market Report

Europe ADHD Therapeutics Market Size

The europe ADHD therapeutics market was valued at USD 3.71 billion in 2025 is expected to have 8.1% CAGR from 2026 to 2034 and be worth USD 7.47 billion by 2034 from USD 4.01 billion in 2026.

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivityy and impulsivity that significantly impair social, al academic, or occupational functioning. In Europe, ADHD therapeutics encompass a range of pharmacological interventions,s including central nervous system stimulants such as methylphenidate and amphetamine, es as well non-stimulantant agents like atomoxetine and guanfacine, which modulate neurotransmitter activity to improve cognitive control and behavioral regulation. Diagnosis and treatment protocols vary across countries but are increasingly guided by evidence-based guidelines from bodies such as the European Society for Child and Adolescent Psychiatry. According to a study, A significant portion of the European population, spanning both children and adults, meets the diagnostic criteria for Attention-Deficit/Hyperactivity Disorder, resulting in millions of individuals being affected. Increased recognition of ADHD, alongside stronger school-based support initiatives, has contributed to better identification and support for affected students in several European nations. The European Medicines Agency has also streamlined approval pathways for pediatric neurotherapeutics, reflecting growing recognition of ADHD as a chronic condition requiring long term management rather than transient behavioral deviation.

MARKET DRIVERS

Increased Early Diagnosis Through School-Based Screening Programs

The systematic integration of mental health assessment in educational settings across several European countries has significantly accelerated ADHD identification, particularly among school-aged children, which drives the growth of the European ADHD therapeutics market. Consequently, this has expanded the eligible treatment population. Several European nations have implemented initiatives within school settings to screen for behavioral health concerns, often featuring collaborative frameworks among educators, families, and healthcare professionals. Certain countries have initiated universal screening measures for neurodevelopmental conditions such as ADHD upon entry into primary education. The implementation of these structured screening programs has been associated with an upward trend in the identification and formal documentation of ADHD cases. Standardized monitoring tools and rating scales are being utilized in schools to identify students who may require further evaluation for potential behavioral conditions. Mental health tracking programs in schools have played a role in identifying a significant number of children with indicators of potential ADHD. Earlier detection enables timely pharmacological intervention during critical neurodevelopmental windows, improving long-term academic and social outcomes. This institutionalized approach not only reduces diagnostic delays but also normalizes therapeutic support, reducing stigma and increasing family willingness to pursue evidence-based care, including FDA andEMA-approvedd medications.

Growing Recognition of Adult ADHD and Its Functional Impairments

Once considered a pediatric condition, ADHD is now increasingly diagnosed in adults across Europe as clinical understanding evolves regarding its persistence and impact on occupational and emotional functioning, propelling the expansion of the European ADHD therapeutics market. A notable number of children experiencing ADHD symptoms continue to face challenges in adulthood, historically often without formal identification or treatment. This discrepancy between the presence of symptoms in adults and formal diagnosis is starting to lessen. Clinical standards are changing to permit adult assessments based on current functional difficulties, even when there is no childhood record, and healthcare systems are making it easier to get adult ADHD evaluations through specific healthcare paths. The use of medication for adult ADHD is increasing, with working adults being a significant group among those getting care. Workplace mental health initiatives in countries like Denmark and the Netherlands now include ADHD awareness training, prompting self-referral. The recognized connection between unmanaged adult ADHD and significant social, occupational, and psychological impairment, specifically unemployment, unstable relationships, and anxiety, has escalated the demand for effective, long-acting treatments throughout adulthood.

MARKET RESTRAINTS

Stringent Regulatory Restrictions on Stimulant Prescribing in Several Countries

Central nervous system stimulants face significant regulatory and prescribing barriers in parts of the region, which hamper the growth of the European ADHD therapeutics market. This is due to concerns over their misuse potential and long-term safety. Several European countries classify methylphenidate as a controlled substance, mandating specialized prescription procedures, limited dispensing quantities, and national registry reporting. Some regions require specific prescriber certification and restrict prescriptions to certain specialists, potentially impacting access, particularly in rural areas. Prescription policies in some jurisdictions limit initial stimulant authorization durations, which can affect treatment continuity and increase administrative tasks. These regulations are often linked to historical caution regarding stimulant medication. Data suggests that diversion rates for pharmaceutical stimulants in the EU remain low. Nevertheless, the regulatory environment discourages physician adoption and pushes clinicians toward less effective non-stimulant alternatives or no pharmacotherapy at all, thereby limiting optimal care pathways for moderate to severe ADHD cases.

Stigma and Cultural Resistance to Pharmacological Treatment in Certain Regions

Persistent societal stigma surrounding psychiatric medication, particularly for children, ren continues to suppress ADHD therapeutic uptake in several European countries despite clinical consensus on treatment benefits, which hinders the expansion of the European ADHD therapeutics market. Societal perspectives on pediatric behavioral medications exhibit significant regional variation, with some populations expressing concern regarding potential changes to a child's temperament or long-term reliance on treatment. In certain regions, educational and advocacy groups actively challenge policies that integrate pharmacological management into the school environment. Public discourse in specific areas may characterize medical interventions as restrictive measures rather than as supportive health options. The clinical recognition of certain neurodevelopmental conditions is not universal, leading to different diagnostic standards and limited availability of specific treatments in some jurisdictions. Even in regions where diagnoses are common, there is a notable tendency to prioritize non-pharmacological management strategies over traditional medication. The decision to pursue medical treatment remains highly dependent on parental discretion, reflecting a cautious approach to pediatric care in various cultural contexts. This cultural hesitancy delays effective intervention, increases academic failure risk,k and perpetuates misconceptions that behavioral issues are purely disciplinary rather than neurobiological in origin.

MARKET OPPORTUNITIES

Expansion of Digital Therapeutics as Adjunct or Alternative Interventions

The emergence of evidence-based digital therapeutics offers a promising opportunity to complement or, in some cases, reduce reliance on pharmacological agents, particularly for mild to moderate ADHD cases, which is expected to boost the growth of theEuropeane ADHD therapeutics market. These software-based interventions, including cognitive training apps, neurofeedback platforms,s and gamified executive function programs, are gaining regulatory recognition across Europe. National health systems are beginning to incorporate digital interventions into their standardized reimbursement frameworks for neurodevelopmental conditions. Prescription-based software is being recognized as a formal therapeutic option alongside traditional medical treatments for pediatric populations. Regulatory bodies are increasingly evaluating and including specialized cognitive training applications within national medicine formularies. Public insurance coverage is expanding to encompass technology-driven therapies designed to address attention-related challenges in children and adolescents. The integration of digital therapeutics into mainstream healthcare reflects a shifting approach toward managing neuropsychiatric health through interactive platforms. The European Commission’s Digital Health Action Plan further supports integration of such tools into standard care pathways, ys emphasizing their potential to enhance adherence,nce reduce side effects, and provide scalable access in underserved regions. As these technologies demonstrate long term efficacy in real-world settings, they are poised to reshape ADHD management paradigms across the continent.

Development of Long-Acting and Abuse-Deterrent Formulations

Pharmaceutical innovation in extended-release and abuse-resistant ADHD medications offers a significant possibility to address key clinical and safety concerns that have historically limited treatment adoption, and thereby is anticipated to fuel the expansion of the European ADHD therapeutics market. Newer formulations, such as once-daily methylphenidate prodrugs and amphetamine salts with pharmacokinetic profiles that minimize peak-trough fluctuations, improve adherence, and reduce rebound symptoms. Several newly authorized long-acting treatments for attention deficit hyperactivity disorder offer more stable medication levels in the bloodstream and extended periods of effectiveness. Certain formulations utilize specific structural or chemical properties designed to make the medication more difficult to alter for unintended use. Regulatory environments that maintain strict controls on stimulant medications may find these design features particularly relevant for clinical practice. Health systems have implemented streamlined processes to provide patients with access to variants specifically engineered to discourage diversion. The transition toward these advanced delivery systems reflects a broader effort to balance therapeutic efficacy with public safety considerations. These advances not only enhance therapeutic reliability but also alleviate prescriber concerns about misuse, enabling broader and more confident use across diverse patient populations,s including adolescents and adults in high-stress academic or professional environments.

MARKET CHALLENGES

Inconsistent Diagnostic Criteria and Access to Specialist Care Across Member States

The lack of harmonized diagnostic frameworks and uneven access to qualified mental health professionals across EU countries is a major challenge in the European ADHD therapeutics market. Diagnostic criteria and assessment procedures for ADHD are not uniform across Europe, with variations observed between regions in the utilization of different diagnostic manuals and multidisciplinary approaches. Regional differences in the emphasis placed on inattentive presentations and adult manifestations of ADHD appear to influence diagnostic rates in different parts of Europe. Discrepancies in formal evaluation rates suggest that access to ADHD diagnosis is not consistent across all European nations. Limited availability of specialists in certain regions creates bottlenecks in the diagnostic process, causing significant delays for initial consultations. Many individuals do not get the care they need because of broken referral systems, insufficient staff, and a lack of early screening, making product availability irrelevant. This systemic fragmentation undermines public health efforts and creates stark disparities in care quality across the region.

Risk of Cardiovascular and Psychiatric Adverse Events With Long-Term Use

Safety concerns regarding the long term cardiovascular and psychiatric effects of ADHD medications remain a persistent clinical and regulatory problem, which limits prescribing confidence, particularly in adolescents and adults with comorbidities, and therefore constrains the expansion of the European ADHD therapeutics market. Investigations into prolonged stimulant use beyond certain timeframes have noted a small, measured increase in resting heart rate and blood pressure, which may increase cardiovascular risks for individuals with underlying vulnerabilities. Longitudinal tracking has observed a higher incidence of cardiac events, including arrhythmias, in individuals on continuous, long-term stimulant therapy. Beyond cardiovascular concerns, psychiatric and physical side effects, such as anxiety, mood lability, and disrupted sleep patterns, are regularly reported in a portion of the patient population. The findings highlight a shift toward closer, regular monitoring of physical and mental health parameters for individuals engaged in long-term treatment. These risks necessitate rigorous pre-treatment screening and ongoing monitoring, which many primary care systems are ill-equipped to provide. Consequently, clinicians often delay or avoid pharmacotherapy even when clinically indicated, resulting in suboptimal symptom control and increased burden on educational and social support systems.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Medication Insights

The stimulants segment was the largest in the European ADHD therapeutics market by accounting for a substantial share in 2025. The dominance of the stimulants segment is attributed to robust clinical evidence demonstrating superior efficacy in reducing core symptoms of inattention and hyperactivity compared to non-stimulant alternatives. Studies indicate that stimulant-based medications, such as those derived from methylphenidate or amphetamine, are commonly linked to a reduction in core symptoms for a significant number of pediatric patients. Clinical guidelines in various regions tend to prioritize these stimulants as an initial medication for children and adults experiencing moderate to severe attention difficulties. Regulatory bodies often require that stimulant medications be used before considering non-stimulant alternatives, unless there are medical reasons against it. Observational data suggest that using long-acting stimulant formulations might be associated with better academic progression rates compared to not receiving treatment. Despite regulatory hurdles in some countries, the clinical superiority and rapid onset of action sustain stimulants as the cornerstone of pharmacological management across Europe.

The non-stimulant medications segment is predicted to witness the highest CAGR of 9.6% from 2026 to 2034 due to increasing demand for alternatives in patients with comorbid anxiety tics or substance use history, where stimulants are contraindicated or poorly tolerated. The presence of comorbidities in a significant portion of patients with ADHD has highlighted the clinical relevance of non-stimulant treatment options. Regulatory bodies have broadened access to alternative therapies for managing ADHD. New, once-daily, selective norepinephrine reuptake inhibitors have received authorization for use, with evidence suggesting minimal impact on cardiovascular metrics. Evidence supporting long-term functional improvements has led to the inclusion of non-stimulant options, such as atomoxetine, in fully reimbursed adult ADHD formularies in certain European jurisdictions. A growing preference among patients and caregivers for non-controlled substances has increased the willingness to adopt non-stimulant treatment approaches. Perceptions surrounding safety have contributed to a higher inclination toward non-stimulant options among caregivers in specific regions. Improved pharmacokinetic profiles are enabling this therapy class to transition from a secondary option to viable primary treatment for a broad spectrum of patients.

By Psychotherapy Insights

The behavior therapy segment led the European ADHD therapeutics market in 2025. The supremacy of the behavior therapy segment is credited to strong endorsement by European clinical guidelines, which position it as the first line non-pharmacological intervention before considering medication. Behavioral therapies are frequently recommended as an initial treatment approach for young children and continue as a core element of care for older children. Healthcare systems in various regions actively support the implementation of these interventions. A significant number of regional youth mental health centers in some areas offer standardized, parent-delivered behavioral programs with public funding. Research analysis suggests that behavior therapy is linked to reduced oppositional behaviors and enhanced classroom compliance. Guidelines within some national health systems propose trialing behavioral interventions before considering medication for children. This policy-driven integration into public care pathways ensures consistent utilization and reimbursement across Western and Northern Europe.

The cognitive behavioral therapy segment is estimated to register the fastest CAGR of 11.2% during the forecast period, owing to expanding recognition of its effectiveness in adolescents and adults,s where executive function deficits manifest as poor time management, emotional dysregulation, and low self-efficacy. Therapeutic approaches specifically modified for neurodevelopmental needs are being increasingly incorporated into national healthcare systems. Legislative updates and policy amendments have enabled broader coverage and reimbursement for specialized behavioral interventions. Healthcare frameworks are evolving to recognize the necessity of adapting traditional psychological therapies for adult populations with specific cognitive profiles. The adoption of remote service delivery models is expanding the availability and reach of behavioral support programs. There is a visible trend toward integrating focused mental health services into public health infrastructure to address functional challenges. Unlike behavior therapy, which targets external behaviors, CBT addresses internal cognitive distortions, making it uniquely suited for older populations seeking autonomy in symptom management. This age-aligned relevance positions CBT as the leading psychological intervention for lifelong ADHD care.

By Education Insights

The Parent Management Training segment dominated the European ADHD therapeutics market in 2025. The prominence of the Parent Management Training segment is driven by its foundational role in early intervention strategies. Endorsed by the European guidelines as essential for children under twelve, it equips caregivers with evidence-based techniques to manage disruptive behaviors, reinforce positive action,s and establish consistent routines. Publicly funded family support centers in certain European regions commonly provide parent management training for young children diagnosed with ADHD. Structured parenting programs, such as "Incredible Years" and "Triple P," are delivered to thousands of families annually, showing positive impacts on family dynamics and school-related behavior. Parenting support initiatives frequently include financial subsidies for lower-income families, promoting greater access to care. International public health and social service entities are actively involved in delivering evidence-based parenting interventions. The approach’s strength lies in its systemic impact; by altering home environment dynamics, it amplifies the effectiveness of both medication and school interventions, creating a multiplier effect across the child’s ecosystem.

The school-based interventions segment is anticipated to witness the fastest CAGR of 12.4% from 2026 to 2034. The swift expansion of the school-based interventions segment is propelled by policy mandates integrating mental health support into educational settings and increasing teacher training in neurodiversity. Many European nations are increasingly adopting structured, individualized planning to support students with ADHD within the school system. Educational systems are placing a greater emphasis on mandatory, ongoing teacher training focused on neurodevelopmental conditions to improve classroom accommodations. Federal education authorities are directing significant resources toward specialized, school-based professional development to address behavioral needs. Collaborative frameworks are being established to bridge the gap between educational institutions, healthcare providers, and families for more cohesive student support. These systemic reforms transform schools from passive observers to active therapeutic partners,s reducing academic failure and social exclusion. School-based programs are shifting from optional support to mandatory, foundational infrastructure in European ADHD care as inclusion becomes a legal mandate.

COUNTRY LEVEL ANALYSIS

Germany ADHD Therapeutics Market Analysis

Germany outperformed other countries in the European ADHD therapeutics market by accounting for a 23.1% share in 2025. The supremacy of the German market is fuelled by its comprehensive healthcare coverage, early diagnosis protocol,s and strong emphasis on multimodal treatment. Observations indicate a substantial number of children and adolescents in Germany are receiving diagnoses for ADHD, with a majority of these cases involving pharmacological interventions covered by public health insurance. Guidelines for ADHD management in Germany emphasize an integrated approach, requiring that care plans incorporate educational and behavioral strategies in conjunction with medication. Germany has broadened its focus on ADHD to include adult populations, with specialized diagnostic and therapeutic services for adults now available across all federal states. The established infrastructure for mental healthcare in Germany facilitates access to cognitive behavioral therapy and other behavioral interventions for individuals with ADHD. Additionally, German regulatory agencies maintain rigorous post-marketing surveillance of ADHD medications through the Paul Ehrlich Institute, enhancing prescriber confidence. This combination of policy, clinical capacity,y and patient access solidifies Germany’s position as the most mature and structured ADHD care market in Europe.

United Kingdom ADHD Therapeutics Market Analysis

The United Kingdom followed closely inthe Europeane ADHD therapeutics market closely by holding a share of 19.1% in 2025. The growth of the Uk market is propelled by its nationalized healthcare approach and progressive integration of digital and psychological interventions. The volume of prescribed medication for attention-related conditions in a specific region has shown a notable upward trend, with a particular stimulant medication representing the majority of dispensed items. Clinical guidelines have been updated to broaden the criteria for adult assessment and to support the reimbursement of digital behavioral interventions. Specialized cognitive-based support pathways for these conditions are being integrated into regional mental health services. Regulatory approval for digital therapeutic interventions, including prescriptive, game-based tools, has been introduced. Despite extended waiting times for specialist evaluations, strategic policy frameworks are being implemented to address delays through early detection in educational settings and enhanced training for primary care providers. This blend of innovation and systemic reform positions the UK as a high-volume and rapidly evolving market.

France ADHD Therapeutics Market Analysis

France is another key player in the European ADHD therapeutics market due to historically cautious pharmacological approaches, but recent policy shifts toward greater recognition and access. The number of individuals receiving medication for attention-deficit hyperactivity disorder has increased annually, suggesting a trend towards higher detection, particularly among adults who were previously underdiagnosed. Updated guidance now supports the use of specific non-stimulant medication as a covered option for adults, especially those experiencing concurrent anxiety symptoms. Prescriptions for stimulant medications are mostly handled by child psychiatrists, but the growth of telepsychiatry has made treatment more accessible in remote regions. Support services for families, such as behavioral training programs, are actively utilized through local municipal channels to assist in managing the condition. Public awareness initiatives have been introduced to address social stigma and to encourage educational accommodations for affected individuals. These reforms signal a transition from skepticism to structured support, making France a high-potential growth market despite lingering cultural barriers.

Netherlands ADHD Therapeutics Market Analysis

The Netherlands grew steadily in the European ADHD therapeutics market owing to its integrated youth mental health system, early intervention mode,,l and strong school collaboration. Childhood ADHD treatment in the Netherlands frequently involves a multi-modal strategy, often combining medication, behavioral support, and educational accommodations soon after identification. The care structure is organized around specialized mental health centers providing centralized, comprehensive services. Governmental efforts are shifting toward enhancing educators' capacity for neurodevelopmental support in classrooms. Stimulant prescribing is liberal yet closely monitored with electronic prescribing linked to the national pharmacovigilance database. Additionally,lly the Netherlands leads in research on non-stimulant alternatives, with Utrecht University conducting Europe’s largest trial on guanfacine extended release in adolescents. This ecosystem of accessibility training and innovation ensures the Netherlands delivers some of the highest quality and most equitable ADHD care in Europe.

Sweden ADHD Therapeutics Market Analysis

Sweden is predicted to expand in theEuropeane ADHD therapeutics market from 2026 to 2034 due to universal healthcare, early screening, and data-driven public health management. Behavioral screening for young children has become a standardized practice, with identified cases prioritized for specialist consultation. The implementation of these proactive measures coincides with an increase in documented attention-related diagnoses. Centralized tracking of care allows for the monitoring of treatment results and continuous improvement in service quality. Coverage for various pharmacological interventions is available, often following a period of structured, behavior-focused support for younger children. Specialized services for adults have grown significantly, with dedicated support now available across all regional areas. Furthermore, Sweden prohibitsoff-labell prescribing, ensuring all medications align with European Medicines Agency approvals. This commitment to evidence-based, equitable, and monitored care makes Sweden a benchmark for systemic ADHD management in Europe.

COMPETITIVE LANDSCAPE

TheEuropeane ADHD therapeutics market features a concentrated yet dynamic competitive landscape dominated by multinational pharmaceutical companies with established central nervous system portfolios. Competition is primarily driven by clinical differentiation, safety profile,s and regulatory navigation rather than price due to stringent public reimbursement systems. While stimulants hold therapeutic dominance, non-stimulant manufacturers compete by targeting specific subpopulations, such as those with comorbid anxiety or cardiovascular risk. Regulatory complexity varies significantly across countries,s creating both barriers and opportunities—companies must tailor market access strategies to individual national guidelines and prescribing restrictions. The rise of digital therapeutics and behavioral interventions adds non-pharmaceutical competition, prompting drugmakers to integrate their products into multimodal care pathways. Additionally growing demand for adult ADHD treatment is attracting new entrants with novel mechanisms of action. This evolving ecosystem demands continuous medical education,n regulatory agility, and patient-centric innovation to sustain market relevance in a region increasingly focused on holistic and evidence-based mental health care.

KEY MARKET PLAYERS

A few of the promising companies operating in the European ADHD therapeutics market profiled in this report are

• Shire plc (Ireland)
• Neos Therapeutics, Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Pfizer Inc. (U.S.)
• Alcobra Ltd. (Israel)
• Supernus Pharmaceuticals, Inc. (U.S.)
• Noven Pharmaceuticals, Inc. (U.S.)
• Novartis AG (Switzerland)
• Johnson & Johnson (U.S.)
• Curemark, LLC. (U.S.)

TOP LEADING PLAYERS IN THE MARKET

• Novartis AG plays a significant role in the European ADHD therapeutics market through its non-stimulant medication Strattera, atomoxetine, which remains a cornerstone treatment for patients with comorbid anxiety or substance use concerns. The company has reinforced its position by supporting real-world evidence studies across Germany, France,e and the UK to demonstrate long-term functional improvements in both children and adults. It also expanded its patient support services to include digital adherence tools and caregiver resources. These initiatives enhance clinical confidence and patient engagement while aligning with Europe’s growing emphasis on holistic and sustainable ADHD management beyond stimulant reliance.
• Takeda Pharmaceutical Company contributes to the European ADHD therapeutics market primarily through its extended-release stimulant formulation based on lisdexamfetamin,e marketed under strict regulatory oversight. The company has strengthened its European footprint by securing expanded indications for adolescent and adult use in multiple countries following positive data from long-term safety trials. It also invested in abuse deterrent packaging and digital tracking systems to address regulatory concerns around stimulant diversion. These actions demonstrate Takeda’s commitment to responsible innovation and broader patient access while navigating Europe’s complex pharmacovigilance and prescribing landscape.
• Jazz Pharmaceuticals has emerged as an influential participant in the European ADHD therapeutics market through its acquisition of a novel stimulant platform featuring smoother pharmacokinetics and reduced peak-related side effects. The company has prioritized regulatory engagement with the European Medicines Agency to fast-track approval of its once-daily formulation for both pediatric and adult populations. It also integrated patient-reported outcome measures into its European clinical trials to align with value-based healthcare demands. These strategic moves position Jazz as a science-driven entrant focused on addressing unmet needs in tolerability and long term adherence across diverse European healthcare systems.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the European ADHD therapeutics market focus on expanding indications for existing molecules to include adolescents and adults, thereby broadening eligible patient populations. They invest inreal-worldd evidence generation to demonstrate functional and academic outcomes, whichsupports reimbursement and guideline inclusion. Companies actively engage with national health technology assessment bodies to secure favorable pricing and access pathways under publicly funded systems. Strategic collaborations with telehealth providers and mental health advocacy groups improve diagnosis rates and treatment initiation, especially in underserved regions. Additionally, our firms enhance product differentiation through abuse deterrent technologies, extended release profiles, and digital adherence tools to address safety concerns and improve long term compliance across diverse European regulatory environments.

MARKET SEGMENTATION

This research report on the europe ADHD Therapeutics Market has been segmented and sub-segmented into the following c.ategories

By Medication

• Stimulants
  • Amphetamines
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
• Non-Stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • Others

By Psychotherapy

• Behavior Therapy
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Family Therapy

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy

By Education

• Parent Management Training
• Social Skills Training
• School-Based Interventions

Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe